An individual capital investment plan to renovate the Mikasa Research Institute and strengthen the research platform for biopharmaceuticals such as anti-HIV antibodies and the production capacity for human-type collagen I and III. The program addresses the renovation work around FY2020 and its impact on research and development expenses.